InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.835 -0.085 (-9.24%)+
Announcement
Release
2 Feb 2026 9:02AM
Price at Release
$0.920
Full Release
download
Summary
Orthocell Limited, an Australian medical technology company, has provided an update on its US market and operational activities as of February 2026. The company is advancing in the commercialization of its RemplirTM product, a nerve repair solution, which is already FDA approved and actively being sold in the US. Orthocell targets a market share of less than 1% for achieving cash breakeven and requires approximately 10,000 units sold annually in the US. They have established a dedicated US team to support growth and have made significant progress with a clear market access strategy. The company is fully funded for expansion, with a cash reserve of approximately AU$49.4 million as of 31 December 2025. Their operational strategy includes expanding manufacturing capabilities to support increased demand, focusing on revenue growth, and building a robust sales infrastructure. Orthocell is also eyeing strategic expansion into the UK, EU, and Asia, with planned launches and increased market penetration. The company’s financial health and strategic direction are supported by a strong leadership team and a comprehensive three-year vision to expand globally and increase shareholder value.
Key Points
  • Orthocell is focused on the commercialization of RemplirTM in the US.
  • FDA approval has been obtained, with sales underway in the US.
  • The company requires approximately 10,000 units in US sales for cash breakeven.
  • Orthocell is well-funded with AU$49.4 million in cash reserves.
  • A dedicated team is in place in the US to support market growth.
  • Manufacturing facilities are being expanded to meet demand.
  • Strategic global expansion plans include the UK, EU, and Asia.
  • The company is focusing on increasing revenue and market share.
  • Leadership includes experienced directors to guide growth.
  • Orthocell is pursuing a clear market access strategy for the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.